protein-engineered interleukin-2 xtx202
Generic: Protein-engineered Interleukin-2 XTX202
protein-engineered interleukin-2 xtx202: 1 clinical trial tracked.
protein-engineered interleukin-2 xtx202 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about protein-engineered interleukin-2 xtx202, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients With Advanced Solid Tumors
Primary endpoint: Incidence of Dose Limiting Toxicities (DLTs) (Phase 1 Part 1A Only)
Interventionalopen95 enrolledStarted 2022-01Completion 2025-0315 sites · United StatesXilio Development, Inc.